A dementia evaluation is a comprehensive medical assessment that combines cognitive testing, medical history review, blood tests, and sometimes brain imaging to determine whether someone has dementia or a reversible condition mimicking its symptoms. A 72-year-old woman reporting increasing forgetfulness might undergo a dementia evaluation, which would include memory tests, attention assessments, conversations about her thinking and language abilities, and possibly an MRI to check for stroke or tumor. The evaluation typically takes several hours across one or more visits and involves a neurologist, primary care physician, or geriatrician who specializes in older adults.
The purpose of a dementia evaluation is not simply to confirm or deny a dementia diagnosis. Instead, evaluators work to identify the specific type of cognitive decline occurring—whether it is Alzheimer’s disease, vascular dementia from small strokes, Lewy body dementia, frontotemporal dementia, or one of many other conditions. Some findings during evaluation may point to treatable causes like vitamin B12 deficiency, thyroid disorder, depression, or medication side effects that mimic dementia but are reversible. This distinction matters enormously because treatment depends on knowing what is actually happening.
Table of Contents
- WHAT COGNITIVE TESTS MEASURE DURING A DEMENTIA EVALUATION
- NEUROPSYCHOLOGICAL TESTING FOR DETAILED COGNITIVE MAPPING
- LABORATORY TESTS AND BLOOD WORK IN DEMENTIA EVALUATION
- BRAIN IMAGING DURING DEMENTIA EVALUATION
- MEDICAL AND MEDICATION REVIEW DURING EVALUATION
- FUNCTIONAL ASSESSMENT AND DAILY LIVING
- MOOD AND BEHAVIORAL ASSESSMENT DURING EVALUATION
- Frequently Asked Questions
WHAT COGNITIVE TESTS MEASURE DURING A DEMENTIA EVALUATION
The cognitive portion of a dementia evaluation assesses multiple mental functions, not just memory. A doctor may administer the Montreal Cognitive Assessment (MoCA), Mini-Cog, or more extensive neuropsychological batteries that test memory, attention, language, visual-spatial skills, and executive function (planning and problem-solving). During one assessment, a patient might be asked to repeat a list of words spoken aloud, then recall those same words several minutes later after completing other tasks. they might copy a drawing of a clock or overlapping pentagons, which tests visual-spatial abilities.
They might name common objects or animals, explain the meaning of proverbs, or perform calculation tasks. These tests are not IQ tests, and scoring lower does not mean someone is less intelligent than they were before. Instead, the tests measure how current cognitive function compares to what would be expected for someone of that person’s age and education level. A retired engineer with college education should perform differently on certain tests than an 85-year-old who completed only eighth grade, and evaluators account for this. The limitation of cognitive testing is that results can be affected by depression, anxiety, poor sleep, pain, or simply being nervous in a doctor’s office—factors that do not indicate dementia but can artificially lower scores.
NEUROPSYCHOLOGICAL TESTING FOR DETAILED COGNITIVE MAPPING
Comprehensive neuropsychological testing goes beyond brief cognitive screening and provides a detailed map of which brain functions are intact and which are declining. A neuropsychologist might spend three to six hours administering specialized tests that examine memory in multiple ways (verbal, visual, immediate, delayed), processing speed, language production and comprehension, reasoning, and impulse control. A patient with Alzheimer’s disease typically shows a particular pattern—memory loss especially prominent, with other cognitive areas less affected early on. In contrast, frontotemporal dementia often shows language or behavioral changes before memory loss becomes obvious, creating a distinct test pattern.
The advantage of detailed neuropsychological testing is that it can detect early cognitive changes, sometimes before symptoms are obvious to the person or family, and it helps differentiate between different types of dementia based on which cognitive domains are impaired. The limitation is cost and time. Comprehensive testing can be expensive and time-intensive, and not all cases require this level of detail. Some evaluations proceed with briefer cognitive screens and imaging only. Additionally, one set of test results provides a snapshot in time; without repeat testing months or years later, it can be hard to confirm whether cognitive decline is genuinely progressive.
LABORATORY TESTS AND BLOOD WORK IN DEMENTIA EVALUATION
Standard blood tests during a dementia evaluation check for treatable causes of cognitive decline: vitamin B12 levels, thyroid function, glucose, liver and kidney function, and sometimes tests for syphilis (tertiary syphilis can cause cognitive impairment). A patient presenting with apparent dementia might have severe B12 deficiency, which causes cognitive changes and confusion that can partially or fully resolve with supplementation. Another might have an underactive thyroid gland (hypothyroidism) that causes slowed thinking and memory problems mimicking early dementia but that improves once hormone replacement begins. Blood tests are also used to detect biomarkers associated with specific dementias.
Researchers have identified that certain proteins in the blood—phosphorylated tau, amyloid-beta—correlate with Alzheimer’s disease pathology, and these biomarker tests are increasingly becoming part of clinical evaluation. One person might have amyloid and tau in their blood but normal cognition on testing, indicating early-stage disease likely to progress. Another might score low on cognitive tests but lack these biomarkers, suggesting a different type of dementia. The warning here is that biomarker tests are relatively new, not yet available at all clinics, and insurance coverage is variable—a person might not have access to these tests even though they could provide valuable information.
BRAIN IMAGING DURING DEMENTIA EVALUATION
MRI (magnetic resonance imaging) or CT (computed tomography) scans are often part of a dementia evaluation to visualize the brain and rule out structural causes of cognitive decline. A patient with sudden memory loss might have an MRI revealing small strokes (vascular dementia), a brain tumor, or normal-pressure hydrocephalus (a treatable condition where cerebrospinal fluid builds up in the brain). These structural causes account for a minority of dementia cases but are critical to identify because some can be treated surgically or medically.
MRI is generally preferred to CT because it provides more detailed images without radiation exposure, though MRI is contraindicated for people with certain metal implants like older pacemakers. Specialized MRI protocols like DTI (diffusion tensor imaging) can show white matter changes associated with vascular dementia. PET scanning (positron emission tomography) can detect amyloid and tau deposits in the brain characteristic of Alzheimer’s disease, but PET is expensive, not widely available, and rarely covered by insurance for dementia diagnosis in routine practice. The comparison between these methods matters: a standard MRI might look “normal” in Alzheimer’s disease (since plaques and tangles are microscopic), so normal brain imaging does not rule out Alzheimer’s; it only rules out stroke, tumor, or hydrocephalus.
MEDICAL AND MEDICATION REVIEW DURING EVALUATION
An evaluator will take a detailed medical history covering past strokes, head injuries, high blood pressure, diabetes, depression, and alcohol use—all risk factors for or contributors to dementia. Medications are reviewed carefully because some drugs contribute to cognitive problems. Anticholinergic medications used for urinary incontinence, antihistamines, or opioids can all cause confusion or memory problems, and sometimes discontinuing or switching these medications improves cognition. A 78-year-old on multiple medications including a strong antihistamine and pain medication might show improvement in memory and attention after doses are reduced or stopped, revealing that the drugs were the primary culprit rather than irreversible dementia.
The limitation is that some medications are necessary despite cognitive side effects, and the causation can be difficult to prove without actually stopping the medication and observing change over weeks or months. Also, some people expect a dementia evaluation to find and fix all cognitive problems, but if testing reveals that medication side effects or depression explain 50% of the cognitive change, there may still be underlying early dementia that requires separate management. A warning: evaluators sometimes find that someone has multiple contributing factors—for example, early Alzheimer’s pathology plus untreated depression plus medication effects all contributing to noticeable cognitive decline. Treating one factor might help, but expecting complete cognitive recovery when disease pathology is present is unrealistic.
FUNCTIONAL ASSESSMENT AND DAILY LIVING
During a dementia evaluation, the clinician assesses how cognitive problems affect daily functioning. Someone might perform relatively well on cognitive tests but have significant problems managing finances, remembering to take medications, preparing meals, or driving safely. These real-world impacts matter more than test scores for determining whether someone has dementia and needs support.
An informant—usually a family member—is asked about whether the person has become lost in familiar places, made unusual financial decisions, left the stove on, or struggled with complex tasks previously done without difficulty. A 65-year-old with early cognitive decline might score borderline on cognitive testing but report that he has stopped paying bills because the process feels too complex now, or he gets confused while driving to once-familiar locations. This functional decline is a key piece confirming dementia. Without functional decline despite cognitive test abnormalities, the findings are more ambiguous—the person might have mild cognitive impairment that may or may not progress to dementia, or the cognitive changes might reflect normal aging rather than pathological decline.
MOOD AND BEHAVIORAL ASSESSMENT DURING EVALUATION
Dementia evaluation includes formal assessment of mood and behavior, since depression and behavioral changes frequently co-occur with or masquerade as dementia. Screening tools for depression, anxiety, and apathy are administered. Some people with mild cognitive impairment also develop depression and worry excessively about memory lapses, which then worsens cognitive performance through stress and inattention (a reversible component). Conversely, some people with early Alzheimer’s disease develop depression as a consequence of noticing their cognitive changes.
Behavioral and personality changes are core features of some dementias. Frontotemporal dementia often begins with socially inappropriate behavior, loss of emotional empathy, or compulsive behaviors before memory loss appears. A spouse might report that their 58-year-old partner has become emotionally flat, makes cruel comments uncharacteristic of his previous personality, or engages in repetitive behaviors like collecting useless items or excessive hand-washing. These behavioral patterns, combined with cognitive testing showing language or executive function deficits, point toward a specific dementia type rather than Alzheimer’s disease. The evaluator documents these behavioral patterns in detail because they shape diagnosis and management.
Frequently Asked Questions
How long does a dementia evaluation take?
A typical evaluation takes two to four hours, sometimes spread across multiple visits. Brief cognitive screening might take 30 minutes, while comprehensive neuropsychological testing can take six hours or more.
Can a dementia evaluation be done in one visit?
Some evaluations, especially brief screening, happen in a single visit. More thorough assessments often require a follow-up appointment for additional testing or to review imaging results.
Does a dementia evaluation always include brain imaging?
Brain imaging (MRI or CT) is strongly recommended but not absolutely required in all cases. Some evaluations proceed with cognitive testing and blood work only, especially if the clinical picture is clear. However, imaging is important to rule out stroke, tumor, or hydrocephalus.
Will the evaluation tell me what type of dementia I have?
The evaluation will indicate which dementia type is most likely based on cognitive patterns, brain imaging, biomarkers, and functional changes. In some cases, the diagnosis is clear. In others, the pattern is mixed and may require time and repeat testing to clarify.
Should a family member be present during the evaluation?
Family or close caregivers should provide history about the person’s daily functioning and changes noticed over time. They may attend part of the appointment, though some cognitive testing is done one-on-one with the clinician.
What if the evaluation finds no dementia despite cognitive concerns?
The evaluation might reveal depression, medication effects, sleep disorder, or normal aging. It might show mild cognitive impairment, a preclinical stage that may or may not progress to dementia, requiring follow-up testing in a year or two.





